COPENHAGEN (Reuters) -Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Joe Biden ...

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...

The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the ...

Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Joe Biden proposed expanding ...

Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...

Shares of Novo Nordisk jumped 1.3% after President Biden proposed expanding Medicare and Medicaid coverage for weight-loss ...

Novo Nordisk (NVO) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now At 40% ...

Massachusetts Financial Services Co. MA grew its position in Novo Nordisk A/S (NYSE:NVO – Free Report) by 2.8% during the 3rd quarter, according to its most recent filing with the Securities and ...

UBS maintained a Hold rating on Novo Nordisk (LSE: 0QIU). 0QIU market cap is currently DKK3305.4B and has a P/E ratio of 35.08. Based on the recent corporate insider activity of 49 insiders, corporate ...

Novo Nordisk's shares rose due to President Joe Biden's proposal to expand Medicare and Medicaid coverage for anti-obesity ...